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Objectives We sought to evaluate the safety and efﬁcacy of bivalirudin compared with glycoprotein
IIb/IIIa inhibitors (GPI) in diabetic patients with ST-segment elevation myocardial infarction (STEMI)
undergoing primary percutaneous coronary intervention (PCI).
Background Prior studies have demonstrated that GPI are especially beneﬁcial in patients with dia-
betes with acute coronary syndromes and/or those undergoing PCI.
Methods In the multicenter, prospective HORIZONS-AMI (Harmonizing Outcomes with Revascular-
iZatiON and Stents in Acute Myocardial Infarction) trial, 3,602 patients with STEMI were randomized
to bivalirudin or unfractionated heparin plus a GPI. Clinical outcomes were analyzed at 30 days and
1 year in patients with diabetes.
Results Diabetes mellitus was present in 593 patients (16.5%). The rates of cardiac death were sig-
niﬁcantly lower in diabetic patients treated with bivalirudin compared with heparin plus GPI
(30 days: 2.1% vs. 5.5%, p  0.04; 1 year: 2.5% vs. 7.1%, p  0.01), and bivalirudin resulted in lower
30-day rates of stroke (0% vs. 2%, p  0.02). There were no signiﬁcant differences among diabetic
patients randomized to bivalirudin versus heparin plus GPI in the 1-year rates of major adverse car-
diac events (14.2% vs. 16.2%, p  0.44), major bleeding (8.7% vs. 10.7%, p  0.42), or stent throm-
bosis (4.2% vs. 3.8%, p  0.85). By interaction testing, the relative effects of bivalirudin compared
with heparin plus GPI were not signiﬁcantly different in patients with and without diabetes.
Conclusions In patients with diabetes mellitus presenting with STEMI undergoing primary PCI, antico-
agulant therapy with bivalirudin compared with heparin plus GPI is safe and effective and might reduce
cardiac mortality at 30 days and 1 year. (Harmonizing Outcomes With Revascularization and Stents in
Acute Myocardial Infarction; NCT00433966) (J Am Coll Cardiol Intv 2011;4:760–8) © 2011 by the
American College of Cardiology Foundation
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761Patients with diabetes mellitus and acute coronary syn-
dromes—both non–ST-segment elevation acute myocardial
infarction (NSTEMI) (1) and ST-segment elevation acute
myocardial infarction (STEMI) (2)—are at greater risk of
death and myocardial infarction compared with patients
without diabetes mellitus. Previous studies have suggested
that glycoprotein IIb/IIIa inhibitors (GPI) improve the
prognosis in diabetic patients, including those undergoing
percutaneous coronary intervention (PCI) for stable isch-
emic heart disease (3,4), for NSTEMI (1,5) and STEMI
(6). However, most of the evidence favoring GPI in STEMI
patients undergoing primary PCI was established in the era
before thienopyridines (7). A recent study demonstrated
that the GPI abciximab does not reduce infarct size or
improve clinical outcomes in STEMI patients within 24 h
of symptom onset treated with dual antiplatelet therapy,
whether diabetic or not (8).
Bivalirudin is a direct thrombin inhibitor with anti-
ischemic properties and favorable bleeding event rates when
used in elective PCI (9), in acute coronary syndromes patients
(10) and STEMI patients treated with primary PCI (11).
However, the impact of bivalirudin in high-risk patients with
diabetes and STEMI undergoing PCI has not been reported.
Therefore, we evaluated the safety and efficacy of bivalirudin in
comparison with treatment with heparin plus GPI in diabetic
patients with STEMI undergoing primary PCI from the
randomized, prospective multicenter HORIZONS-AMI
(Harmonizing Outcomes with RevasculariZatiON and Stents
in Acute Myocardial Infarction) trial.
Methods
Patient population and study protocol. The HORIZONS-
AMI study design has been previously described in detail
(11,12). In summary, the HORIZONS-AMI trial was a
prospective, open-label, randomized, multicenter trial in
which 3,602 patients with STEMI presenting within 12 h
of symptom onset and undergoing a primary PCI manage-
ment strategy were randomized 1:1 to bivalirudin alone
versus unfractionated heparin plus a GPI (the control
group). After angiography, eligible patients were random-
ized again in a 3:1 ratio to either TAXUS Express
paclitaxel-eluting stents or otherwise identical uncoated
Express bare-metal stents (Boston Scientific, Natick, Mas-
sachusetts). The study was approved by the institutional
and Regado Sciences, and has received research support from Bristol-Myers Squibb/
sanofi-aventis. Dr. Guagliumi serves as a consultant for Boston Scientific, Volcano,
and Cordis, and has received research grant support from Medtronic, Boston
Scientific, LightLab Imaging, and Abbott Vascular. Dr. Dudek has received research
grants or served as consultant/advisory board member for Abbott, Adamed, Biotro-
nik, Balton, Bayer, BBraun, BioMatrix, Boston Scientific, Boehringer, Ingelheim,
Bristol-Myers Squibb, Cordis, Cook, Eli Lilly, EuroCor, GlaxoSmithKline,
Invatec, Medtronic, The Medicines Company, Merck Sharp & Dohme, areview board or ethics committee at each participating
center, and all patients signed informed consent.
Patient eligibility criteria has also been described previ-
ously (11–13). In summary, consecutive patients 18 years
of age with symptom onset within 12 h of duration and
ST-segment elevation of 1 mm in 2 contiguous leads,
new left bundle branch block, or true posterior myocardial
infarction were considered for enrollment. Principal exclu-
sion criteria included contraindications to any of the study
medications; prior administration of fibrinolytic therapy,
bivalirudin, GPI, low molecular weight heparin, or fonda-
parinux for the present admission (prior unfractionated
heparin was allowed); current use of coumadin; history of
bleeding diathesis, conditions predisposing to hemorrhagic
risk, or refusal to receive blood transfusions; stroke or
transient ischemic attack within 6 months or any permanent
neurological deficit; recent or known platelet count 100,000
cells/mm3 or hemoglobin 10
/dl; planned elective surgical pro-
edure that would necessitate in-
erruption of thienopyridines
uring the first 6 months after
nrollment; coronary stent im-
lantation within 30 days; and
oncardiac comorbid conditions
ith life expectancy 1 year or
hat might result in protocol non-
ompliance.
Endpoints and statistical analysis.
The 2 primary endpoints of the
HORIZONS-AMI trial were
major bleeding (not related to
coronary artery bypass grafting)
and net adverse clinical events
(NACE), defined as the combi-
nation of major bleeding or ma-
jor adverse cardiovascular events
(MACE). Major adverse cardiovascular events comprised
death, reinfarction, target vessel revascularization for isch-
emia, or stroke. The endpoint definitions have been detailed
elsewhere (12). Bleeding was adjudicated according to the
protocol definition (11) as well as on the basis of the
Thrombolysis In Myocardial Infarction (TIMI) and
GUSTO (Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries)
scales. Stent thrombosis was defined according to the Aca-
ycomed, Orbus-Neich, Pfizer, Possis, Promed, Sanofi-Aventis, Siemens, Solvay,
erumo, and Tyco. Dr. Stuckey serves on the Speakers’ Bureau and medical
dvisory board for Boston Scientific. Dr. Stone serves as a consultant to Boston
cientific, Abbott Vascular, The Medicines Company, Merck, Eli Lilly, Astra-
eneca, and Bristol-Myers Squibb-Sanofi. All other authors have reported that
hey have no relationships to disclose.
anuscript received February 15, 2011; revised manuscript received April 4, 2011,
Abbreviations
and Acronyms
GPI  glycoprotein IIb/IIIa
inhibitor
MACE  major adverse
cardiovascular event(s)
NACE  net adverse clinical
event(s)
NSTEMI  non–ST-segment
elevation acute myocardial
infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation acute myocardial
infarction
TIMI  Thrombolysis in
Myocardial Infarctionccepted April 13, 2011.
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762demic Research Consortium classification (14). Noncardiac
death was defined as a death not due to cardiac causes,
including bleeding-related death. All primary and secondary
endpoint events were adjudicated by a clinical events commit-
tee using original source documents, blinded to treatment
assignment.
Diabetes was defined as a history of hyperglycemia
managed by insulin, oral hypoglycemic agents, or diet.
Categorical outcomes were compared by chi-square test or
Fisher exact test. Continuous variables were compared by
means of the Wilcoxon rank-sum test. Time-to-event
outcomes, determined with Kaplan-Meier methods, were
compared by the log-rank test. Independent correlates of
30-day and 1-year mortality in the entire randomized
population and in the cohort undergoing primary PCI were
determined by Cox proportional hazards regression.
Results
Patients and procedures. Of 3,602 patients with STEMI
undergoing primary PCI and enrolled in the HORIZONS-
AMI trial, 593 patients (16.5%) had diabetes mellitus. This
included 159 (26.8%) treated with insulin, 322 (54.3%) treated
Table 1. Baseline Characteristics According to Diabetic Status
Variable
Diabete
Bivalirudin
(n  281)
Heparin
(n 
Age, yrs 64.4 [55.8, 71.5] 64.5 [56
Male 70.5 (198) 76.3 (2
Insulin-treated diabetes 25.6 (72) 27.9 (8
Hypertension 73.7 (207) 70.8 (2
Hyperlipidemia 64.4 (181) 56.1 (1
History of smoking 53.0 (148) 60.5 (1
Prior myocardial infarction 17.8 (50) 15.7 (4
Prior PCI 15.7 (44) 17.3 (5
Prior CABG surgery 5.7 (16) 5.1 (1
Weight, kg 85.0 [77.0, 95.0] 85.0 [75
BMI, kg/m2 29.4 [26.1, 32.0] 28.5 [25
Symptom onset to hospital arrival, h 2.0 [1.0, 3.8] 2.5 [1.
Killip class 2–4 12.9 (36) 11.9 (3
Qualifying electrocardiogram (core laboratory)
Left bundle branch block 2.3 (6/265) 1.8 (5
ST-segment elevation* 96.5 (250/259) 96.7 (2
Other* 3.5 (9/259) 3.3 (9
Creatinine clearance 60 ml/min 18.1 (47) 20.5 (6
Anemia† 14.2 (38) 16.4 (4
Thrombocytopenia‡ 6.3 (17) 5.2 (1
Left ventricular ejection fraction§ 50 [45, 60] 48 [38
Values are median [25th, 75th percentile] or % (n). *Excluding left bundle branch block; †hemato
§visual assessment from the baseline contrast left ventriculogram.
BMI body mass index; CABG coronary artery bypass grafting; GPI glycoprotein IIb/IIIa inhiwith oral medications without insulin, and 107 (18.0%) treatedwith diet alone. Of those, 281 patients were randomized to
anticoagulant treatment with bivalirudin, and 312 were ran-
domized to heparin plus a GPI. The baseline features and
procedural data in patients randomized to bivalirudin versus
heparin plus a GPI were well-matched in the diabetic and
nondiabetic cohort (Tables 1 and 2). Among patients with
diabetes, there were no significant differences in management
strategy after coronary angiography: PCI was subsequently
performed in 92.2% of the bivalirudin-treated group and in
91.7% of the heparin plus GPI group (p  0.82), coronary
artery bypass grafting without PCI was subsequently per-
formed in 2.1% versus 3.5%, respectively (p  0.31), and
medical management was subsequently performed in 5.7 versus
4.8%, respectively (p  0.63). Thienopyridine use before
admission was slightly higher in the diabetic patients random-
ized to heparin plus GPI, and the percentage of angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers
at discharge was slightly lower in nondiabetic patients random-
ized to bivalirudin (Table 2).
Clinical outcomes in diabetic and nondiabetic patients.
Among the diabetic cohort, there were no significant differ-
ences in the rates of NACE, MACE, all-cause mortality, or
major bleeding events in patients assigned to bivalirudin versus
No Diabetes
PI
p Value
Bivalirudin
(n  1,518)
Heparin Plus GPI
(n  1,488) p Value
.1] 0.61 59.3 [51.1, 68.7] 59.8 [52.4, 69.6] 0.15
0.11 78.3 (1,189) 76.1 (1,133) 0.15
0.53 0 (0) 0 (0)
0.44 47.7 (724) 51.9 (772) 0.02
0.04 39.5 (600) 39.9 (594) 0.83
0.07 67.9 (1,025) 61.9 (917) 0.0006
0.50 9.0 (137) 10.5 (156) 0.18
0.60 9.5 (144) 10.5 (156) 0.86
0.76 2.8 (43) 2.0 (30) 0.15
.0] 0.41 80.0 [70.0, 90.0] 80.0 [70.0, 90.0] 0.86
.8] 0.20 26.8 [89.0, 105.0] 26.8 [24.4, 29.7] 0.61
0.11 1.84 [1.00, 3.17] 1.66 [0.92, 3.03] 0.11
0.72 7.7 (117) 7.7 (115) 0.99
0.69 1.0 (14/1,402) 1.0 (13/1,358) 0.91
) 0.89 97.8 (1,355/1,386) 97.3 (1,306/1,342) 0.45
0.89 2.2 (31/1,386) 2.7 (36/1,342) 0.45
0.46 15.3 (215) 16.8 (232) 0.31
0.48 9.7 (139) 9.5 (133) 0.87
0.58 3.2 (47) 4.6 (66) 0.05
0.001 50 [45, 60] 50 [44, 60] 0.75
e at initial presentation 39% for men and 36% for women; ‡150,000 cells/mm3 at baseline;
CI percutaneous coronary intervention.s
Plus G
312)
.3, 72
38)
7)
21)
75)
88)
9)
4)
6)
.0, 97
.7, 31
5, 4.3]
7)
/281)
67/276
/276)
0)
9)
6)
, 55]
crit valuheparin plus GPI at 30 days (Table 3). However, bivalirudin
o
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763treatment was associated with a significantly reduced 30-day
rate of cardiac death (2.1% vs. 5.5%, p 0.04) and stroke (0%
vs. 2.0%, p  0.02). Noncardiac mortality was higher at 30
days with bivalirudin, however (1.4% vs. 0%, p 0.05), and as
such there was no significant difference in all-cause mortality
between the 2 therapies.
At 1 year, of the rate of cardiac mortality in diabetic patients
was significantly reduced with bivalirudin compared with
heparin plus GPI (2.5% vs. 7.1%, p 0.01), and the difference
in noncardiac mortality was no longer significant (2.2% vs.
0.7%, p 0.12). All-cause mortality at 1 year occurred in 4.7%
f diabetic patients treated with bivalirudin compared with
.8% treated with heparin plus GPI (p 0.13). There were no
significant differences in the 1-year rates of NACE, MACE,
and major bleeding according to assigned treatment (Fig. 1).
Among nondiabetic patients, randomization to bivalirudin
Table 2. Procedures and Medications According to D
Variable
Diabete
Bivalirudin
(n  281)
Heparin Pl
(n  31
Infarct-related artery
Left anterior descending 40.1 (109) 45.6 (1
Left circumﬂex 18.0 (272) 12.5 (3
Right coronary artery 40.4 (110) 39.3 (1
Left main 0.7 (2) 0.3 (1
Saphenous vein graft 0.7 (2) 2.3 (7
Heparin before procedure 65.5 (184) 67.6 (2
Antithrombin during procedure
Heparin 2.1 (6) 99.0 (3
Bivalirudin 95.7 (269) 0.3 (1
GPI IIb/IIIa inhibitor
In the cath lab, any 8.6 (24) 94.2 (2
Abciximab 3.9 (11) 47.1 (1
Eptiﬁbatide 4.6 (13) 46.8 (1
Tiroﬁban 0.0 (0) 0.3 (1
Aspirin use
Before admission 44.1 (124) 39.1 (1
During hospitalization 98.9 (278) 100.0 (3
At discharge 98.2 (267) 97.0 (2
Thienopyridine use
Before admission 2.5 (7) 6.1 (1
Loading dose, any 95.7 (269) 95.8 (2
Clopidogrel 300 mg 35.9 (101) 37.8 (1
Clopidogrel 600 mg 59.1 (166) 56.7 (1
At discharge 93.0 (253) 92.3 (2
Medications at discharge
Beta-blockers 90.0 (253) 87.4 (2
ACE inhibitors or ARB 81.6 (222) 75.3 (2
Statins 93.8 (255) 95.0 (2
Values are % (n).
ACE  angiotensin-converting enzyme; ARB  angiotensin recept
inhibitor.resulted in a significant reduction of NACE (at 30 days: 8.8%vs. 11.9%, p 0.005; at 1 year: 14.7% vs. 17.5%, p 0.03) and
major bleeding (at 30 days: 4.7% vs. 8.6%, p  0.0001; at 1
year 5.3% vs. 9.0%, p  0.0001), with nonsignificant differ-
ences in MACE (Fig. 1, Table 3).
Further analysis of the diabetic patients according to
insulin-treated and noninsulin-treated cohorts did not re-
veal any significant differences of bivalirudin or heparin plus
GP IIb/IIIa treatment for NACE or major adverse clinical
or bleeding events, whereas there was a significant advan-
tage in favor of bivalirudin treatment among insulin-treated
patients with regard to cardiac death at 1 year (1.4% vs.
9.4%, p  0.04) (Fig. 2, Table 4).
Formal interaction testing demonstrated that the fa-
vorable effects of bivalirudin compared with heparin plus
GPI in reducing the 1-year rates of major bleeding,
NACE, all-cause mortality, and cardiac mortality in the
ic Status
No Diabetes
p Value
Bivalirudin
(n  1,518)
Heparin Plus GPI
(n  1,488) p Value
0.18 39.1 (595) 41.2 (610) 0.24
0.06 16.2 (246) 15.8 (233) 0.74
0.79 42.8 (650) 41.9 (620) 0.64
0.60 0.7 (11) 0.4 (6) 0.25
0.18 1.1 (16) 0.7 (10) 0.27
0.58 65.6 (994) 65.1 (968) 0.81
0.0001 2.6 (40) 98.9 (1,469) 0.0001
0.0001 97.1 (1,472) 0.5 (7) 0.0001
0.0001 6.9 (105) 94.5 (1,405) 0.0001
0.0001 4.0 (61) 50.5 (750) 0.0001
0.0001 2.8 (43) 43.9 (652) 0.0001
1.00 0.1 (2) 0.2 (3) 0.68
0.21 23.6 (358) 24.5 (364) 0.59
0.11 99.8 (1,513) 99.8 (1,483) 1.00
0.37 98.1 (1,462) 97.1 (1,406) 0.07
0.03 3.7 (56) 4.1 (61) 0.57
0.95 97.2 (1,473) 97.0 (1,442) 0.84
0.64 32.6 (494) 33.6 (500) 0.54
0.56 63.3 (959) 61.5 (914) 0.32
0.76 93.8 (1,399) 92.8 (1,344) 0.30
0.32 89.1 (1,346) 88.4 (1,308) 0.58
0.67 73.6 (1,098) 77.3 (1,120) 0.02
0.52 93.7 (1,397) 93.6 (1,356) 0.90
er; cath lab  catheterization laboratory; GPI  glycoprotein IIb/IIIaiabet
s
us GPI
2)
39)
8)
20)
)
)
11)
01)
)
94)
47)
46)
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26)
85)
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764status (pint  0.26, 0.64, 0.55, and 0.19, respectively).
Similarly, bivalirudin compared with heparin plus GPI
resulted in nonsignificantly different rates of MACE,
noncardiac mortality, and stroke in the entire study
population (12), effects which were also independent of
diabetic status (pint  0.38, 0.17, and 0.06, respectively).
Stent thrombosis. The overall rate of definite/probable
stent thrombosis at 1 year did not differ among diabetic
patients who received bivalirudin compared with those
treated with heparin plus GPI (4.2% vs. 3.8%, p  0.85).
Similarly, there was no difference in the 1-year rates of
stent thrombosis between the randomized antithrombotic
regimens in the nondiabetic subgroup (3.5% vs. 3.1%,
p  0.54) (Table 5), and interaction testing for an effect
f diabetic status on stent thrombosis by randomization
as negative (p  0.93). There were also no significant
ifferences in the rate of stent thrombosis between the 2
reatment arms when the diabetic patients were further
eparated into insulin-treated or non–insulin-treated
roups (Table 5).
iscussion
Diabetic patients presenting with STEMI have a substan-
tially greater incidence of early and late death or myocardial
Table 3. Clinical Outcomes at 30 Days According to
Dia
Bivalirudin
(n  281)
Hep
GPI
Net adverse clinical events 12.5 (35) 1
Major adverse cardiac events 6.4 (18)
Death (all-cause) 3.6 (10)
Cardiac 2.1 (6)
Noncardiac 1.4 (4)
Reinfarction 2.2 (6)
Q-wave 1.8 (5)
Non–Q-wave 0.4 (1)
TVR 3.3 (9)
Stroke 0.0 (0)
Major bleeding (non–CABG-related) 7.9 (22) 1
Major bleeding (including CABG-related) 11.9 (33) 1
Blood transfusion 4.3 (12)
TIMI classiﬁcation
TIMI major bleeding 6.9 (19)
TIMI minor bleeding 4.0 (11)
GUSTO classiﬁcation
Life-threatening or severe bleeding 0.4 (1)
Moderate bleeding 6.1 (17)
Values are % (n).
CABG coronary artery bypass graft surgery; GPI glycoprotein I
Arteries; MACE  major adverse cardiovascular event(s) (death, m
PCI percutaneous coronary intervention; TIMI Thrombolysis in Minfarction compared with nondiabetic subjects (15–17). mWith contemporary interventional approaches, the proce-
dural success rate of primary PCI in diabetic patients with
STEMI is equivalent to nondiabetic patients, as rein-
forced in the present report (16,18). However, diabetic
patients with STEMI compared with nondiabetic pa-
tients are less likely to achieve normal myocardial perfu-
sion (as measured by reduced restoration of normal
angiographic myocardial blush and ST-segment resolu-
tion, and a greater incidence of distal embolization),
which has been associated with higher mortality
(2,18,19). Glycoprotein IIb/IIIa inhibitors might im-
prove myocardial perfusion and survival (20,21), partic-
ularly in patients with diabetes. In the ADMIRAL
(Abciximab before Direct angioplasty and stenting in
Myocardial Infarction Regarding Acute and Long-term
follow-up) trial (6), the 6-month rates of mortality and
target vessel revascularization after primary stenting were
reduced in the 53 diabetic patients randomized to abcix-
imab versus placebo (mortality: 0% vs. 16.7%, p  0.02;
target vessel revascularization: 3.7% vs. 37.5%, p 
.046). However, this result was not reproduced in the
arger CADILLAC (Controlled Abciximab and Device
nvestigation to Lower Late Angioplasty Complications)
rial with 346 diabetic patients enrolled (22,23). A
tic Status
No Diabetes
lus
12) p Value
Bivalirudin
(n  1,518)
Heparin Plus GPI
(n  1,488) p Value
) 0.20 8.8 (133) 11.9 (177) 0.0005
) 0.16 5.3 (80) 4.7 (70) 0.45
) 0.28 1.8 (27) 2.6 (39) 0.12
) 0.04 1.7 (26) 2.4 (35) 0.22
0.05 0.1 (1) 0.3 (4) 0.17
0.57 1.9 (28) 1.6 (23) 0.52
0.69 1.4 (21) 1.0 (15) 0.34
0.37 0.5 (7) 0.6 (9) 0.59
0.81 2.7 (40) 1.8 (27) 0.12
0.02 0.9 (14) 0.4 (6) 0.08
) 0.33 4.7 (70) 8.6 (127) 0.0001
) 0.72 6.1 (92) 11.0 (162) 0.0001
) 0.78 1.8 (27) 3.5 (52) 0.003
) 0.40 2.6 (39) 5.3 (78) 0.0002
) 0.50 2.7 (40) 4.6 (68) 0.004
0.37 0.5 (8) 0.5 (8) 0.97
) 0.78 2.7 (40) 4.9 (72) 0.001
hibitor; GUSTO Global Strategies for Opening Occluded Coronary
ial infarction, ischemic target vessel revascularization, or stroke);
l Infarction; TVR target vessel revascularization.Diabe
betes
arin P
(n  3
6.4 (51
9.6 (30
5.5 (17
5.5 (17
0.0 (0)
2.9 (9)
2.3 (7)
1.0 (3)
2.9 (9)
2.0 (6)
0.3 (32
2.9 (40
4.9 (15
5.2 (16
5.2 (16
1.0 (3)
6.9 (21
Ib/IIIa in
yocardeta-analysis based on individual specific data from the ISAR-2
diabe
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765(Intracoronary Stenting and Antithrombotic Regimen-2) (24),
ADMIRAL (6), and ACE (Abciximab-Carbostent Evalua-
tion) (25) studies including 183 diabetic patients reported
that death and reinfarction were significantly lower in
diabetic patients treated with abciximab compared with
UFH alone (26).
We have previously reported that patients randomized to
bivalirudin rather than heparin plus GPI in the
HORIZONS-AMI trial benefitted from a pronounced
reduction in bleeding events, along with NACE and all-
cause and cardiac mortality (11,27). However, a recent
meta-regression analysis suggested that the benefits from
adjunctive GPI in improving survival are most evidenced in
high-risk patients, such as those with diabetes mellitus (28).
With this background, the current report in 593 diabetic
patients enrolled in the HORIZONS-AMI trial represents
the largest analysis of diabetic STEMI patients treated by
contemporary primary PCI to date and demonstrates that
bivalirudin compared with heparin plus GPI significantly
reduces cardiac mortality in the high-risk diabetic cohort as
well as patients without diabetes.
Although cardiac mortality and stroke were reduced in
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Figure 1. Kaplan-Meier Curves Through 1 Year for NACE, MACE, Major Ble
Kaplan-Meier curves through 1 year for (A) net adverse clinical events (NACE);
coronary artery bypass grafting (CABG); and (D) cardiac mortality, according todiabetic patients treated with bivalirudin rather than hepa-rin plus GPI, total mortality, major bleeding, and NACE
were not significantly reduced in the diabetic cohort with
bivalirudin. However, interaction testing demonstrated
that the relative reductions in bleeding, NACE, and
all-cause and cardiac mortality with bivalirudin compared
with heparin plus GPI were not significantly different in
the diabetic and nondiabetic groups. Given that sub-
groups are inherently underpowered (29), the most ap-
propriate interpretation of these data is that the overall
benefits with bivalirudin seen in the main trial seem to
apply to patients both with and without diabetes. How-
ever, we cannot exclude a modest difference in the relative
effect of bivalirudin versus heparin plus GPI in patients
with versus without diabetes. Moreover, previous studies
have suggested a higher rate of stent thrombosis in
diabetic patients, particularly those insulin-treated
(30,31). In the present analysis the overall rate of stent
thrombosis in the diabetic subgroup was comparable in
patients treated with bivalirudin or those treated with
heparin plus GPI.
In the HORIZONS-AMI trial, study medications were
most commonly initiated in the catheterization laboratory.
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766start of GPI therapy might be beneficial before primary PCI
in STEMI. A recent meta-analysis of 281 diabetic patients
from 11 randomized trials of early versus late administration
Figure 2. Subgroup Analyses: 1-Year Rates of NACE and Major Bleeding
Subgroup analyses: hazard ratios with 95% conﬁdence intervals for the 1-year
the overall study population and according to diabetic status, for insulin-treate
study population. *For cardiac mortality among insulin-treated diabetic patien
value being 0.037, because the former is calculated from a Cox model and the
Table 4. Clinical Outcomes at 1 Year According to In
Insulin-Treate
Bivalirudin
(n  72)
Heparin
(n 
Net adverse clinical events 28.9 (20) 24.6
Major adverse cardiac events 19.3 (13) 18.8
Death (all-cause) 4.4 (3) 10.6
Cardiac 1.4 (1) 9.4
Noncardiac 3.0 (2) 1.3
Major bleeding (non–CABG-related) 16.9 (12) 10.5
Values are % (n).Abbreviations as in Table 3.of GPI in STEMI found that upstream GPI was associated
with significant improvements in pre- and post-procedural
TIMI flow and myocardial perfusion (distal embolization,
of NACE, major bleeding not related to CABG, MACE, and cardiac death, in
non–insulin-treated diabetic patients, nondiabetic patients, and overall
95% conﬁdence interval of the hazard ratio crosses unity, despite the p
from the log-rank. Abbreviations as in Figure 1.
Treatment in Patients With Diabetes
etes NonInsulin-Treated Diabetes
PI
p Value
Bivalirudin
(n  209)
Heparin Plus GPI
(n  225) p Value
0.58 17.4 (36) 21.0 (47) 0.30
0.97 12.6 (26) 15.3 (34) 0.40
0.15 4.8 (10) 6.7 (15) 0.41
0.04 2.9 (6) 6.3 (14) 0.10
0.45 2.0 (4) 0.5 (1) 0.16
0.23 6.9 (14) 11.7 (26) 0.09rates
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767myocardial blush grade); however, complete ST-segment
resolution, enzymatic infarct size, and—most importantly—
mortality at 1 year (8.3% vs. 9.5%) was not improved (32).
Therefore, it is unlikely that systematic early administration
of GPI in the HORIZONS-AMI trial would have had a
significant impact on the results overall and in the diabetic
subgroup.
Study limitations. First, although the present diabetic anal-
sis was a pre-specified substudy, the HORIZONS-AMI
rial was not powered for subgroup analysis. As such, despite
he large number of diabetic patients enrolled, these results
hould be considered exploratory and hypothesis-
enerating. Second, the open-label design of the study
ight have introduced potential bias. However, all clinical
vents were adjudicated by an independent clinical events
ommittee blinded to all procedural medications. Third, as
s common in all such substudies, diabetes was diagnosed on
dmission according to prior history and not by glucose or
nsulin level testing. It is possible that serial testing of
iabetic state might have identified a high-risk diabetic
roup more prone to benefit with either bivalirudin or
eparin plus GPI. This is unlikely, however, given the
egative interaction testing from the present analysis and
he comparable results with both regimens in patients with
nsulin treatment.
onclusions
The HORIZONS-AMI diabetes substudy demonstrates
that, in both high-risk patients with diabetes and nondia-
betic patients with STEMI undergoing primary PCI, anti-
coagulation with bivalirudin monotherapy (with bail-out
GPI in 7.6% of patients for refractory thrombotic compli-
cations) compared with heparin plus the routine use of a
GPI seems to significantly improve 30-day and 1-year net
Table 5. Stent Thrombosis at 1 Year According to Di
Diabetes
Bivalirudin
(n  281)
Heparin Plus GPI
(n  312)
Deﬁnite or probable 4.2 (10) 3.8 (10)
Deﬁnite 3.8 (9) 2.3 (6)
Probable 0.4 (1) 1.5 (4)
Insulin-Treated Diabetes
Bivalirudin
(n  72)
Heparin Plus GPI
(n  87)
Deﬁnite or probable 9.8 (6) 10.4 (8)
Deﬁnite 8.3 (5) 5.2 (4)
Probable 1.6 (1) 3.9 (3)
Values are % (n). Stent thrombosis definition according to Academic R
GPI glycoprotein IIb/IIIa inhibitor.clinical outcomes and survival.Reprint requests and correspondence: Dr. Gregg W. Stone,
Columbia University Medical Center, The Cardiovascular Re-
search Foundation, 111 East 59th Street, 11th Floor, New York,
New York 10022. E-mail: gs2184@columbia.edu.
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